[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100621258":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":10,"centralContacts":19,"locations":10,"responsibleParty":25,"collaborators":10,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":10,"eligibilityCriteria":35,"healthyVolunteers":31,"sex":36,"minAge":37,"maxAge":38,"enrollmentInfo":39,"targetDuration":10,"studyType":42,"phases":43,"briefSummary":45,"conditions":46,"keywords":10,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":49,"lastUpdatePostDateStruct":50,"startDateStruct":53,"completionDateStruct":55,"leadSponsor":57,"locationsCount":10},{"fullName":5,"class":6},"Jiangxi Provincial Cancer Hospital","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"limited-field radiotherapy Group",null,[12],"Radiation: limited-field radiotherapy",[14],{"type":15,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"RADIATION","limited-field radiotherapy","limited-field radiotherapy + Concurrent and adjuvant TMZ chemotherapy",[9],[20],{"name":21,"role":22,"phone":23,"phoneExt":10,"email":24},"Ziwei Tu","CONTACT","13755793552","tuziwei198803@163.com",{"type":26,"investigatorFullName":27,"investigatorTitle":28,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Zhiping Chen","Director of the Head and Neck Radiation Therapy Department，Jiangxi cancer Hospital","100621258","limited-target-volume-radiotherapy-after-glioblastoma-surgery-100621258",false,"NCT07368283","Limited Target Volume Radiotherapy After Glioblastoma Surgery","A Single-arm Phase II Non-inferiority Clinical Study of Limited Target Volume Radiotherapy After Glioblastoma Surgery","Inclusion Criteria:\n\n* Aged between 18 and 70 years.\n* Diagnosed with glioblastoma by surgical pathology, with the extent of resection achieving maximal safe resection.\n* Within 2 to 6 weeks after surgery\n* In good physical condition with a Karnofsky Performance Status (KPS) score ≥ 60.\n* Hematological, hepatic, and renal functions are essentially normal.\n* Signed informed consent, willing to undergo treatment and follow-up as stipulated in the study protocol.\n\nExclusion Criteria:\n\n* Prior history of cranial radiotherapy or other malignant tumors.\n* Severe dysfunction of vital organs (e.g., heart, liver, kidneys) that precludes tolerance to radiotherapy.\n* Active infection, immune system disorders, or other serious chronic diseases.\n* Pregnancy or lactation.\n* Psychiatric disorders or severe cognitive impairment that compromises the ability to cooperate with treatment and follow-up.","ALL","18 Years","70 Years",{"count":40,"type":41},79,"ESTIMATED","INTERVENTIONAL",[44],"NA","Research on radiotherapy target volumes for glioblastoma is increasingly focused on exploring more limited yet effective irradiation fields, aiming to achieve local control while minimizing acute and long-term neurotoxicity. Previous retrospective analysis by investigators revealed that local recurrences of glioblastoma are predominantly confined to a narrow margin around the original lesion: 98.3% of recurrences occurred within 0.5 cm of the original T2-FLAIR abnormality, 94.8% within 1 cm of the original T1-enhanced region. These findings have been cited in the ESTRO-EANO treatment guidelines. Building on this evidence, investigators plan to conduct a single-arm, phase II clinical trial to systematically evaluate the efficacy and safety of a 1 cm radiotherapy target volume in post-operative glioblastoma patients.Eligible patients with glioblastoma who have undergone surgical resection will be selected to receive limited-field radiotherapy. The target volume will be defined based on the postoperative MRI enhancing lesion: a 1 cm margin will be added to form the clinical target volume (CTV), followed by a further 0.3 cm margin to create the planning target volume (PTV). A total dose of 60 Gy will be delivered in 30 fractions (2 Gy per fraction, 5 fractions per week). Concurrent and adjuvant chemotherapy will be administered per standard guidelines. The primary efficacy endpoints are the 6-month progression-free survival rate and the incidence of symptomatic radiation-induced brain necrosis of grade 3 or higher. Secondary endpoints include overall survival, patterns of recurrence, neurocognitive function, and quality of life.",[47],"Glioblastoma (GBM)","NOT_YET_RECRUITING","2026-01-28",{"date":51,"type":52},"2026-01-30","ACTUAL",{"date":54,"type":41},"2026-01",{"date":56,"type":41},"2030-12",{"name":5,"class":6}]